Evaluation of Eslicarbazepine-loaded reduced Graphene oxide Polymeric nanoparticles by Pentylenetetrazole (PTZ) induced convulsion in mice

  • Unique Paper ID: 166465
  • Volume: 8
  • Issue: 8
  • PageNo: 645-650
  • Abstract:
  • Millions of people worldwide suffer greatly from epilepsy, a chronic neurological illness that severely lowers quality of life. Typical antiepileptic medications frequently have negative side effects, low absorption, and inadequate patient compliance. The objective of this research is to devise and evaluate polymeric nanoparticles loaded with escicarbazepine to improve the treatment of epilepsy. A new antiepileptic medication called eslicarbazepine acetate has encouraging therapeutic potential, however its physicochemical characteristics limit its clinical usefulness. In this paper, we investigated polymeric nanoparticles loaded with Eslicarbazepine using biocompatible and biodegradable polymers. They are put through in-vivo release experiments to look at the kinetics of eslicarbazepine's release from the polymeric nanoparticles. To ascertain the drug release mechanisms and guarantee a prolonged and regulated release, the release profiles were examined. The outcomes showed that the polymeric nanoparticles offered Eslicarbazepine a stable and effective delivery mechanism, increasing its bioavailability and therapeutic efficiency. According to our research, polymeric nanoparticles loaded with Eslicarbazepine may be able to minimize adverse effects and lower the frequency of doses, which would increase patient compliance and treatment results overall. This study demonstrates how medication delivery systems based on nanotechnology may transform the way epilepsy is treated and lays the groundwork for future in vivo research and clinical use.

Related Articles